• Castle Biosciences disclosed a published study on TissueCypher use in non-dysplastic Barrett’s esophagus at a specialist surgery center.
• Clinicians shifted patient management in 90% of cases once test results were available, pointing to broad impact on care decisions.
• Results supported more intensive follow-up or treatment for higher-risk patients, while backing less intensive surveillance for lower-risk patients.
• Findings were presented on Sept. 27 at the American College of Surgeons Clinical Congress 2026 in Washington, D.C.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609280700PR_NEWS_USPR_____DA56565) on September 28, 2026, and is solely responsible for the information contained therein.